Verona Pharma plc
("Verona Pharma" or the "Company")
Director's Dealing
26 November 2014, Cardiff, UK- Verona Pharma plc (AIM: VRP.L) (the "Company") received notification on 25 November 2014 that on that date, Mr Stuart Bottomley, a non-executive director of the Company, acquired via his SIPP an interest in 500,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 1.45 pence per share.
Following the acquisition, Mr. Bottomley will have an interest in the Company of 18,750,000 Ordinary Shares, representing 1.86% of the Company's issued ordinary share capital.
-Ends-
For further information please contact:
Verona Pharma plc |
Tel: +44 (0) 20 7863 3300 |
Jan-Anders Karlsson, CEO |
|
|
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Julia Phillips / Simon Conway |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing.